Natco Pharma Pledges $22 Million in Investment in eGenesis to Advance Organ Engineering
Natco Pharma Limited has significantly increased its commitment to eGenesis, Inc., by investing an additional US$ 14 million. This new investment, made through two of its wholly owned subsidiaries, brings Natco’s total investment in the biotechnology firm to US$ 22 million.The investment aims to support eGenesis's pioneering work in genome engineering, which is focused on developing safe and effective transplantable organs to combat the global organ shortage.
The new tranche of investment involves NATCO Pharma (Canada) Inc. committing US$ 9.5 million and NATCO Pharma South Africa Proprietary Limited contributing US$ 4.5 million. These funds are allocated through convertible promissory notes.
Previously, in 2024, Natco Pharma Limited had invested US$ 8 million in eGenesis, Inc. through preferred stock. The collective investment now stands at US$ 22 million.
eGenesis, which is based in Cambridge, Massachusetts, USA, is utilizing its Genome Engineering and Production (EGEN platform). This technology is noted as the only one designed to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering. The company is advancing development programs for kidney transplant, acute liver failure, and heart transplant.
eGenesis has achieved notable milestones, including the world's first porcine kidney transplant in a living patient, announced in March 2024. This transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway, followed by two additional porcine kidney transplants in other patients.
The financial details of the current investment are structured as follows:
| Subsidiary | Principal Amount | Instrument | Interest Rate |
|---|---|---|---|
| NATCO Pharma (Canada) Inc. | US$ 9.5 million | Convertible Promissory Note | 8% compounded annually |
| NATCO Pharma South Africa Proprietary Limited | US$ 4.5 million | Convertible Promissory Note | 8% compounded annually |
The investment is scheduled for completion by September 30, 2026.
eGenesis, a biotechnology company, was incorporated on October 1, 2015, and is focused on transforming solid organ and therapeutic cell transplantation. The company is currently in clinical trials for porcine kidney transplantation in humans and porcine liver perfusion.
Natco Pharma Limited is a R&D oriented and science driven company that develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients, and crop protection products. Its facilities are approved by various regulatory authorities, including the US FDA and Health Canada.
NATCOPHARM Stock Price Movement
Natco Pharma Limited shares slipped today by 1.98% to settle at ₹866.55. The stock recorded a total traded volume of 394,394 shares in post-market trading.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.